Trial Profile

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Seclidemstat (Primary)
Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Sarcoma; Solid tumours
Focus Adverse reactions; Biomarker
Sponsors Salarius Pharmaceuticals

Most Recent Events

14 Oct 2021 Status changed from recruiting to completed.
08 Jun 2021 Interim results (Data cut off 30 Dec 2020, n=19) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
07 Jun 2021 According to an Salarius Pharmaceuticals media release, data from this trial presented at the at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com